Aug. 8 at 8:57 PM
$OMER - "This is Miguel Parales. I'm the Chief of the Adult BMT program at Memorial Sloan Kettering. And I do need to disclose that I have financial interest related to merit. I think as you've heard, the drug is FDA approved for patients with TA-TMA. And I do think that it's going to be a paradigm shift in the sense that I've actually treated some patients already on the expanded access study, and we have intervened early in the disease course. We have not waited for them to get really sick because we know that those patients are harder to recover. And I think where the big difference has been that historically, you would withdraw the immunosuppressive drugs, typically tacrolimus, cyclosporine, which were among the main offenders and patients typically would develop acute GvHD despite whatever you did. And many patients died either of GvHD or of TA-TMA or of complications related to eculizumab, particularly infectious complications."
